Low Vitamin B12 May Increase Risk for Bleeding Strokes theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.
Two new analyses from the DELIVER Phase III trial presented at European Society of Cardiology’s Heart Failure 2023 congress in Prague, Czech Republic support the consistent benefits of Farxiga regardless of heart failure (HF) duration1 and across the spectrum of cardiovascular, renal and metabolic (CVRM) .
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER .